retatrutide ly3437943 parkinson's disease clinical trial Incretin triple agonist (LY3437943) alleviates obesity-associated cancer progression Retatrutide Results: 28.3% Weight Loss – Many Parkinson's clinical trials fail

So it's just not a good product for me

The vials are labeled "for research purposes only, not for human consumption." This labeling is what allows them to sell the product without FDA approval, since technically they are selling a lab chemical, not a medicine

Millipore), Mouse/Rat PYY EIA (YK081, Yanaihara Institute, Inc.), and Human/Rat/Mouse Cholecystokinin Octapeptide (26-33, non-sulfated) EIA kits (Phoenix Pharmaceuticals, Inc.), respectively

Neither currently prohibits GLP-1 drugs

The LIV Body Enrollment Process - Step by Step, With What to Expect LIV Body's lander describes a three-step process

Dose Ranges Tested Different strengths were tested in Phase II studies, with higher doses delivering the most dramatic weight-loss effects